Structure activity relationship of selected polyphenol derivatives as inhibitors of Bax/Bcl-xL interaction

Université de Rennes1, Laboratoire Sciences Chimiques de Rennes, CNRS UMR 6226, Avenue du Général Leclerc, 35042 Rennes Cedex, France.
European Journal of Medicinal Chemistry (Impact Factor: 3.45). 02/2012; 51:286-93. DOI: 10.1016/j.ejmech.2012.02.036
Source: PubMed


This paper describes the synthesis of nine selected diaryl/heteroaryl-containing phenol and polyphenol derivatives which have been evaluated against Bax/Bcl-xL interaction in comparison with ABT-737. Using a BRET assay, six of these derivatives exhibit activity comparable to ABT-737 to disrupt Bax/Bcl-xL interaction. These preliminary results demonstrate that such polyphenol-derived molecules are attractive compounds regarding anticancer activity and that the phenol at position 3 is important regarding disruption of Bax/Bcl-xL interaction.

Download full-text


Available from: Duc-Duy Vo, Sep 24, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Plant polyphenols are considered among the most abundant phytochemicals that are present in human diets, and their regular consumption has been associated with reduced risk of a number of chronic diseases, including cancer, and cardiovascular and neurodegenerative disorders. In the past decades, plant polyphenols have drawn increasing scientific attention due to their potent antioxidant and other properties and their marked effects in the prevention of various oxidative stress-associated diseases. Recently, the polyphenolic extracts from different plants have become a major area of health- and medical-related research. This review provides an update and comprehensive overview of various plant polyphenolic compounds, and the quantification of their antioxidant properties, anticancer activities, and therapeutic effects. Also, the review discusses the current scientific knowledge of various plant polyphenols to inhibit tumorigenesis in animal models and to modulate cell signaling pathways involved in inflammation and the development of malignant tumors, and related biochemical interventions in cell function under both normal and pathological conditions. We present in vitro and in vivo studies (in experimental animals) in which polyphenols showed increased anticancer potential. Also, numerous epidemiological research data and findings from human intervention studies, as well preclinical studies supporting cancer prevention mechanisms. Lastly, we present recent clinical trials for anticancer action of certain polyphenols that showed promising anticancer and therapeutic properties.
    Studies of Natural Products Chemistry, Volume 39, Amsterdam edited by Atta-ur-Rahman, 01/2013: chapter 8: pages 269-295; Elsevier., ISBN: 978-0-444-62615-8
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Embelin is a natural product, inhibitor of XIAP (X-chromosome-linked Inhibitor of APoptosis) with strong proapoptotic properties on cancer cells. In order to clarify the role of two OH groups on benzoquinone core, we have prepared by hemisynthesis close analogues of embelin, where these OH have been replaced in a systematic manner by OMe and OAc groups. Proapoptotic activities of six embelin derivatives have been studied as single agent, or in combination with TRAIL, and their abilities to interact with XIAP have been evaluated by Surface Plasmon Biacore. Our results show that these new embelin analogues have good proapoptotic properties against selected cancer cells, often higher than the natural product itself. Further, this activity is not directly mediated by XIAP. Altogether these preliminary results demonstrate that for active embelin analogues, the two OH are not absolutely required for anticancer activity, opening new possibilities for the design of proapoptotic derivatives in these series.
    Medicinal chemistry (Shāriqah (United Arab Emirates)) 01/2013; 9(8). DOI:10.2174/1573406411309080003 · 1.36 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: For many years the spotlight in drug discovery has been on a relatively small number of validated therapeutic target classes, such as G-protein coupled receptors and enzymes such as protein kinases, with well characterized enzymatic and cellular activities. However, with recent progress in genomics and proteomics, protein-protein interactions (PPIs) provide new way of finding novel bioactive molecules acting on their interfaces. This review addresses the current case studies and state of the art in the development of small chemical modulators controlling interactions of proteins that have pathological implications in various human diseases and in particular in cancer. The attention is focused on Bcl-2 family protein modulators ranging from natural products to synthetic ones with particular interest in foldamers as BH3 alpha helix mimetics.
    Current Medicinal Chemistry 05/2013; 20(24). DOI:10.2174/0929867311320240003 · 3.85 Impact Factor
Show more